Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Trop Med Hyg ; 106(2): 678-680, 2021 11 29.
Article in English | MEDLINE | ID: mdl-34844211

ABSTRACT

Diarrhea in an immunocompromised patient has a broad infectious differential. Diagnosis is difficult despite advances in diagnostic modalities. We report a case of a 45-year-old Nigerian woman who immigrated to the United States 2 years ago. She presented to the hospital with gastrointestinal bleeding, newly diagnosed HIV, and disseminated Kaposi sarcoma. During hospitalization, the patient had an onset of watery diarrhea and high eosinophilia. Subsequent stool analysis using multi-parallel real-time quantitative polymerase chain reaction for 13 parasites was positive for Cystoisospora belli. The patient was treated with trimethoprim-sulfamethoxazole, but had relapsed disease when her antibiotics were stopped prematurely. After restarting trimethoprim-sulfamethoxazole, her diarrhea and eosinophilia improved, and she had undetectable Cystoisospora belli DNA on repeat stool quantitative polymerase chain reaction. This case highlights the importance of a thorough workup for diarrhea, including parasites, especially for immunocompromised patients. Antibiotic prophylaxis is recommended in patients with Cystoisospora belli and HIV/AIDS.


Subject(s)
Diarrhea/diagnosis , Eosinophilia/diagnosis , Gastrointestinal Hemorrhage/diagnosis , HIV Infections/diagnosis , Immunocompromised Host , Isosporiasis/diagnosis , Sarcoma, Kaposi/diagnosis , Anti-Infective Agents/therapeutic use , Diarrhea/drug therapy , Diarrhea/immunology , Diarrhea/parasitology , Eosinophilia/drug therapy , Eosinophilia/immunology , Eosinophilia/parasitology , Female , Gastrointestinal Hemorrhage/drug therapy , Gastrointestinal Hemorrhage/immunology , Gastrointestinal Hemorrhage/parasitology , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/parasitology , Humans , Isospora/immunology , Isosporiasis/drug therapy , Isosporiasis/immunology , Isosporiasis/parasitology , Middle Aged , Sarcoma, Kaposi/drug therapy , Sarcoma, Kaposi/immunology , Sarcoma, Kaposi/parasitology , Treatment Outcome , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
2.
Sex Transm Dis ; 44(4): 227-232, 2017 04.
Article in English | MEDLINE | ID: mdl-28282649

ABSTRACT

BACKGROUND: Little is known about the lifetime risk of human immunodeficiency virus (HIV) diagnosis among US men who have sex with men (MSM), trends in risk and how risk varies between populations. METHODS: We used census and HIV surveillance data to construct life tables to estimate the cumulative risk of HIV diagnosis among cohorts of MSM born 1940 to 1994 in King County, Washington (KC) and Mississippi (MS). RESULTS: The cumulative risk of HIV diagnosis progressed in 3 phases. In phase 1, risk increased among MSM in successive cohorts born 1940 to 1964. Among men born 1955 to 1965 (the peak risk cohort), by age 55 years, 45% of white KC MSM, 65% of black KC MSM, 22% of white MS MSM, and 51% of black MS MSM had been diagnosed with HIV. In phase 2, men born 1965 to 1984, risk of diagnosis among KC MSM declined almost 60% relative to the peak risk cohort. A similar pattern of decline occurred in white MS MSM, with a somewhat smaller decline observed in black MS MSM. In phase 3, men born 1985 to 1994, the pattern of risk diverged. Among white KC MSM, black KC MSM, and white MS MSM, HIV risk increased slightly compared with men born 1975 to 1984, with 6%, 14%, and 2% diagnosed by age 27 years, respectively. Among black MS MSM born 1985 to 1994, HIV risk rose dramatically, with 35% HIV diagnosed by age 27 years. CONCLUSIONS: The lifetime risk of HIV diagnosis has substantially declined among MSM in KC and among white MSM in MS, but is rising dramatically among black MSM in MS.


Subject(s)
HIV Infections/epidemiology , Health Status Disparities , Life Tables , Racial Groups/statistics & numerical data , Sexual and Gender Minorities/statistics & numerical data , Adult , Black or African American/statistics & numerical data , Cohort Studies , Geography , HIV Infections/ethnology , Humans , Male , Middle Aged , Mississippi/epidemiology , Risk Factors , Washington/epidemiology , White People/statistics & numerical data , Young Adult
3.
Cancer Invest ; 28(3): 289-94, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20073579

ABSTRACT

Radiotherapy with chemotherapy for rectal cancer reduces local recurrence risk. Of 113 patients (59 male, 54 female) undergoing treatment at New York Presbyterian Hospital, 1998-2007, 6 discontinued radiotherapy; all were female. Females were also more likely to have a treatment interruption (35% vs 12%, p = .004). Other factors associated with treatment interruption included adjuvant versus neoadjuvant therapy (OR 14.08, 95%CI 1.55-127.87), use of capecitabine versus 5-fluorouracil (OR 75.90, 95%CI 3.33->999), and development of any adverse event (OR 20.66, 95%CI 1.76-242.12). While radiotherapy discontinuation was uncommon in our cohort, for unknown reasons, females were more likely to discontinue or interrupt treatment.


Subject(s)
Rectal Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Female , Humans , Logistic Models , Male , Middle Aged , Patient Compliance , Rectal Neoplasms/drug therapy , Sex Characteristics
SELECTION OF CITATIONS
SEARCH DETAIL
...